$MYL (Mylan N.V.)

$MYL {{ '2016-07-20T17:54:38+0000' | timeago}} • Announcement

$MYL announced the U.S. launch of Rosuvastatin Calcium Tablets, which is a generic version of $AZN's Crestor. $MYL received final approval from FDA for its Abbreviated New Drug Application for this product. The tablets are used in combination with diet to treat high triglycerides (hypertriglyceridemia) in adults.

$MYL {{ '2017-09-14T19:22:15+0000' | timeago}} • Announcement

$MYL announced the US launch of Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, which is indicated for use by women to prevent pregnancy. $MYL’s subsidiary, Mylan Laboratories Limited, received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for this product.

$MYL {{ '2017-09-13T15:45:16+0000' | timeago}} • Announcement

$MYL appointed Dennis Zeleny as chief human relations officer. Zeleny joins Mylan with 30 years of experience leading global, corporate HR organizations and consulting on HR policy matters.

$MYL {{ '2017-09-08T21:46:48+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. Pfizer is continuing to work with the FDA to resolve the points raised in the warning letter regarding Pfizer’s manufacturing of the EpiPen products and Mylan will do whatever it can to support this process.

$MYL {{ '2017-09-08T21:46:14+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. The letter was issued in connection with FDA's inspection of Pfizer’s pharmaceutical manufacturing facility located in Brentwood, Missouri, where the EpiPen products are manufactured.

$MYL {{ '2017-08-17T20:41:08+0000' | timeago}} • Announcement

$MYL, a pharma company, announced that its subsidiaries, Mylan Inc. and Mylan Specialty L.P., have signed an agreement with the U.S. Department of Justice and two relators. This is to finalize the Medicaid drug rebate settlement that the company announced on Oct 7, 2016 for $465MM.

$MYL {{ '2017-08-10T14:13:12+0000' | timeago}} • Announcement

Pharma company $MYL has launched three generic drugs for HIV treatment, in Canada. The company recently received final approval for the products from Health Canada. The new products offer generic alternative to popular HIV drugs Truvada, Atripla and Viread.

$MYL {{ '2017-08-09T21:34:36+0000' | timeago}} • Announcement

$MYL cut down its outlook for FY17, hit by the price erosion and delay in the launch of its new drugs. Mylan lowered its revenue expectation to $11.5-12.5Bil from the prior range of $12.25-13.75Bil. Adjusted EPS target was cut down to $4.30-4.70 from the prior estimate of $5.15-5.55 for FY17, and from $6.00 to currently "at least $5.40" for FY18.

$MYL {{ '2017-08-09T21:09:46+0000' | timeago}} • Announcement

$MYL, which got the approval to launch its HIV drug in India recently, reported a 76% jump in 2Q17 profit, aided by the acquisition of Swedish drugmaker Meda last year. Net earnings were $297MM in the quarter and GAAP EPS surged 67% to $0.55. Revenue grew 16% to $2.96Bil, while adjusted EPS slipped 5% to $1.10.

$MYL {{ '2017-08-09T15:03:57+0000' | timeago}} • Infographic

$MYL Mylan N.V. Earnings AlphaGraphic: Q2 2017 Highlights

$TBPH {{ '2017-07-20T12:32:48+0000' | timeago}} • Announcement

$TBPH and $MYL announced positive results from a 12-month Phase 3 safety study of revefenacin in patients with chronic obstructive pulmonary disease (COPD). The study of 1,055 patients with COPD demonstrated that revefenacin was generally well-tolerated, and no new safety issues were identified.

$MYL {{ '2017-07-14T12:05:52+0000' | timeago}} • Announcement

Pharma firm $MYL said the FDA Oncologic Drugs Advisory Committee has recommended approval of the biosimilar trastuzumab developed by Mylan along with India-based Biocon Ltd. for  treatment of breast cancer. The committee determined no clinically meaningful differences exist between the biosimilar product and cancer drug Herceptin.

$TBPH {{ '2017-05-23T15:28:15+0000' | timeago}} • Announcement

$TBPH and $MYL announced the presentation of additional efficacy and safety data from the three-month, pivotal Phase 3 studies of revefenacin at the American Thoracic Society International Conference in Washington, D.C. Revefenacin is an investigational long-acting muscarinic antagonist.

$MYL {{ '2017-05-10T15:37:21+0000' | timeago}} • Webcast

On the Advair issue, $MYL said the Food and Drug Administration (FDA) has not asked the company to do any additional clinical endpoints or device related studies. The FDA has rejected the company's generic version of Advair, a $GSK's drug to treat asthma and chronic lung conditions.

$MYL {{ '2017-05-10T15:14:54+0000' | timeago}} • Webcast

In terms of new products, $MYL said it is working towards the roadmap of launching new products worth about $850MM for 2017. The company is on track on generating $850MM from those new product introductions and expects the launches to be heavier in 2H17.

$MYL {{ '2017-05-10T12:55:59+0000' | timeago}} • Infographic

$MYL Mylan N.V. Earnings AlphaGraphics: Q1 2017 highlights

$MYL {{ '2017-05-10T12:08:49+0000' | timeago}} • Announcement

$MYL's third party net sales in all three of its segments increased for 1Q17, helped by net sales from the acquisition of Meda and the Topicals Business. In North America, third party net sales increased 5% YoY to $1.21Bil, while in Europe net sales increased 53% to $892MM. Rest of World third party net sales increased 34% to $580.5MM.

$MYL {{ '2017-05-10T12:01:51+0000' | timeago}} • Announcement

Generic pharmaceutical company $MYL reported higher 1Q17 earnings, positively impacted by the increase in earnings from operations. Net income increased 377.69% to $66.4MM or $0.12 per share from $13.9MM or $0.03 per share a year ago. Revenue increased 24.1% YoY to $2.71Bil. Excluding items, $MYL earned $0.93 per share, up 22% YoY.

$MYL {{ '2017-05-01T17:25:57+0000' | timeago}} • Announcement

$MYL's BoD nominated Sjoerd Vollebregt as a candidate for election to its Board at the 2017 Annual Meeting to be held on June 22, 2017. The directors Douglas Leech, Joseph Maroon and Rodney Piatt will retire from the Board effective June 22, 2017 and have not been nominated for reelection at the Annual Meeting.

$MYL {{ '2017-04-20T18:47:12+0000' | timeago}} • Announcement

$MYL announced the US launch of Perphenazine Tablets, a generic version of the reference listed drug, Trilafon Tablets, originally marketed by Schering. $MYL received final approval from the US FDA for its ANDA for this product, used in treatment of schizophrenia and for the control of severe nausea and vomiting in adults.

$MYL {{ '2017-03-28T13:54:33+0000' | timeago}} • Announcement

Pharmaceutical company $MYL appointed Daniel Gallagher as Chief Legal Officer. Gallagher will be joining the company on April 17, 2017.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
MYL (Mylan N.V.)
Wednesday, August 9 2017 - 2:00pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
Thursday, July 27 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm

AlphaGraphics you may like